Impetigo Clinical Trial
Official title:
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
The purpose of this study is to document the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with bacterial infections, including impetigo, folliculitis, and minor soft tissue infections including secondarily infected eczema presumed to be caused by methicillin resistant Staph aureus. Male and female patients ages 9 months to 98 years will be recruited from a university based dermatology clinic. Upon enrollment, wound cultures will be collected, and then subjects will apply topical retapamulin twice daily for five days. The primary endpoint will be resolution of methicillin-resistant Staphylococcus aureus (MRSA) infection based on clinical presentation and physical exam, as well as bacteriological efficacy based on culture results. It is anticipated that approximately 75 patients will be enrolled, with expectation that approximately 50 of these patients will have MRSA infections.
Status | Completed |
Enrollment | 38 |
Est. completion date | November 2012 |
Est. primary completion date | November 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 9 Months to 98 Years |
Eligibility |
Inclusion Criteria: - Male or female patients from 9 months of age up to 98 years of age. - Clinical diagnosis of impetigo, folliculitis, or minor soft tissue infection including secondarily infected eczema presumed to be caused by Staphylococcus aureus. - The patient, and if applicable the parent or guardian, is able to give informed consent - Females of child bearing potential have a negative urine pregnancy test. - Patient, and if applicable parent or guardian, are willing to and capable of complying with the study protocol. Exclusion Criteria: - Subject who has used a topical antibacterial medication to the area being treated within the last 48 hours. - Subject who has been enrolled in a clinical trial within the last 30 days. - Subject with signs of systemic infection (such as fever), or with evidence of abscess or cellulitis at the site to be treated. - Subject has a bacterial skin infection which would not be appropriately treated by a topical antibiotic in the opinion of the investigator - Subjects who have taken oral antibiotics within the last 7 days. - Subjects with known sensitivity to the study medication. - The subject is pregnant or breastfeeding |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Houston Medical Center Building | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
The University of Texas Health Science Center, Houston | GlaxoSmithKline |
United States,
Bohaty BR, Choi S, Cai C, Hebert AA. Clinical and bacteriological efficacy of twice daily topical retapamulin ointment 1% in the management of impetigo and other uncomplicated superficial skin infections. International Journal of Women's Dermatology 1: 13
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants Whose Wound Cultures Were Positive for MRSA and Who Were Determined to be a Clinical Success at the Follow-up Visit | Clinical success is defined as no further signs or symptoms of infection present, including erythema, purulence, crusting, edema, warmth and pain. | 6 to 8 days after treatment | No |
Secondary | Clinical Response at Follow up as Assessed by a Rating Scale | Clinical response was based on clinical evaluation by the investigator at the follow-up visit using a predefined scale with the following categories: (1) clinical success, (2) clinical improvement, (3) no change, (4) clinical failure, and (5) unable to determine. Patients who were designated as clinical success as defined in number 1 above were considered a true "clinical success" while all others were considered a "clinical failure." Patients were classified with an outcome of "unable to determine" if they missed their follow-up visit or refused clinical examination. | 6 to 8 days after treatment | No |
Secondary | Microbiologic Response at Follow up as Assessed by a Rating Scale | Microbiological response was determined by the investigator at the follow-up visit using the following microbiological outcomes: (1) microbological eradication, (2) presumed microbiological eradication, (3) presumed microbiological improvement, (4) microbiological persistence, (5) presumed microbiological persistence, (6) unable to determine, (7) new pathogen, and (8) colonization. Patients who were designated microbiological eradication, presumed microbiological eradication, presumed microbiological improvement, or colonization as defined in numbers 1, 2, 3, and 8 above were considered a "microbiological success" while all others were considered "microbiological failure." | 6 to 8 days after treatment | No |
Secondary | Number of Participants Who Were a Therapeutic Success | Therapeutic response was determined from the clinical response and the microbiological response. Patients who qualified as both a "clinical success" and a "microbiological success" were deemed a "therapeutic success," and all others were deemed "therapeutic failures." | 6 to 8 days after treatment | No |
Secondary | Erythema (Sign and Symptom of Infection) at Baseline | Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. | baseline | No |
Secondary | Erythema (Sign and Symptom of Infection) at Follow up | Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. | 6 to 8 days after treatment | No |
Secondary | Purulence (Sign and Symptom of Infection) at Baseline | Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. | baseline | No |
Secondary | Purulence (Sign and Symptom of Infection) at Follow up | Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. | 6 to 8 days after treatment | No |
Secondary | Crusting (Sign and Symptom of Infection) at Baseline | Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. | baseline | No |
Secondary | Crusting (Sign and Symptom of Infection) at Follow up | Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. | 6 to 8 days after treatment | No |
Secondary | Tissue Edema (Sign and Symptom of Infection) at Baseline | Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. | baseline | No |
Secondary | Tissue Edema (Sign and Symptom of Infection) at Follow up | Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. | 6 to 8 days after treatment | No |
Secondary | Tissue Warmth (Sign and Symptom of Infection) at Baseline | Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. | baseline | No |
Secondary | Tissue Warmth (Sign and Symptom of Infection) at Follow up | Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. | 6 to 8 days after treatment | No |
Secondary | Pain (Sign and Symptom of Infection) at Baseline | Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. | baseline | No |
Secondary | Pain (Sign and Symptom of Infection) at Follow up | Signs and symptoms of infection were classified as one of the following: absent, minimal, moderate, or severe. | 6 to 8 days after treatment | No |
Secondary | Wound Size at Baseline | Wound size area was determined by measuring the greatest length of the wound in two perpendicular dimensions with a standard metric ruler. The two measurements were multiplied together to provide an estimate of the overall wound size. Surrounding erythema was not included in the measurement. | baseline | No |
Secondary | Wound Size at Follow up | Wound size area was determined by measuring the greatest length of the wound in two perpendicular dimensions with a standard metric ruler. The two measurements were multiplied together to provide an estimate of the overall wound size. Surrounding erythema was not included in the measurement. | 6 to 8 days after treatment | No |
Secondary | Number of Participants Reporting Any Adverse Event (AE) | AEs included burning at application site, upper respiratory infection, furuncle, cough, and a rash at a site other than the application site. See the Adverse Events section for more detailed information. | baseline to 6 to 8 days after treatment | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00884728 -
Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory
|
N/A | |
Completed |
NCT02902822 -
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
|
N/A | |
Completed |
NCT01153828 -
EU PV for Retapamulin-Prescribing
|
N/A | |
Active, not recruiting |
NCT05226260 -
Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care
|
N/A | |
Terminated |
NCT00986856 -
Fucidin® Cream in the Treatment of Impetigo
|
Phase 4 | |
Completed |
NCT01397461 -
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
|
Phase 3 | |
Recruiting |
NCT02090764 -
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
|
Phase 3 | |
Completed |
NCT02775617 -
Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
|
Phase 4 | |
Not yet recruiting |
NCT01611909 -
Citriodiol® and Impetigo
|
Phase 2/Phase 3 | |
Completed |
NCT03177993 -
Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji
|
N/A | |
Completed |
NCT03429595 -
Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo
|
Phase 2 | |
Completed |
NCT04287777 -
Safety and Efficacy of Mupirocin Gel in Children With Impetigo
|
Phase 3 | |
Completed |
NCT00626795 -
Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)
|
Phase 2 | |
Completed |
NCT00758862 -
The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo
|
Phase 2 | |
Recruiting |
NCT01943136 -
The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial
|
Phase 1 | |
Completed |
NCT01670032 -
Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo
|
Phase 2/Phase 3 | |
Completed |
NCT01171326 -
Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients
|
Phase 2 | |
Completed |
NCT01367314 -
Safety and Efficacy of Topical NVC-422 Gel in Impetigo
|
Phase 2 | |
Completed |
NCT00852540 -
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
|
Phase 3 | |
Completed |
NCT00133848 -
Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment
|
Phase 3 |